Loading...
XKRX
039200
Market cap739mUSD
May 02, Last price  
27,350.00KRW
1D
-0.73%
1Q
2.43%
Jan 2017
282.52%
IPO
1,160.37%
Name

Oscotec Inc

Chart & Performance

D1W1MN
No data to show
P/E
1,180.13
P/S
30.42
EPS
23.18
Div Yield, %
—
Shrs. gr., 5y
5.30%
Rev. gr., 5y
50.75%
Revenues
34.01b
+586.89%
24,755,850,12021,858,819,38017,110,321,00018,335,817,6103,553,891,3963,908,490,78018,702,671,5114,368,519,89943,470,793,3843,902,734,7525,062,376,4934,950,929,99934,007,602,680
Net income
877m
P
-14,476,368,760-3,970,862,400-2,022,401,030395,029,229-3,645,623,319-5,856,532,8603,470,819,696-22,435,600,783-4,356,524,883-26,262,552,170-24,429,544,991-24,279,525,966876,526,890
CFO
-26.03b
L+18.08%
3,335,386,500-1,345,620,790-1,962,080,260645,418,561-3,369,209,475-3,689,052,797-5,077,994,13027,468,801-17,881,396,374-8,761,867,982-26,420,974,927-22,047,670,110-26,033,707,910
Dividend
Dec 29, 200850 KRW/sh
Earnings
May 12, 2025

Profile

Oscotec Inc. operates as a clinical stage drug discovery and development company. It develops SYK inhibitor that is in Phase IIa clinical trial to treat rheumatoid arthritis and immune thrombocytopenia; FLT3 inhibitor, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; and EGFR double mutation inhibitor to treat non-small cell lung cancer, as well as Anti-Tau antibody, which is in preclinical Phase for the treatment of Alzheimer's disease. The company also offers dental health products, such as bone graft comprising InduCera, BioCera-F, and SynCeraII; and membrane consisting of LysoGide and CollaGuide. In addition, it provides functional ingredients comprises OPB for osteoporosis; AIF for arthritis; SGA that enhance bone growth; and PRF-K for perio diseases. The company was formerly known as Oscotec Co., Ltd and changed its name to Oscotec Inc. in June 1999. Oscotec Inc. was founded in 1988 and is based in Seongnam, South Korea.
URL
http://www.oscotec.com/
IPO date
Jan 17, 2007
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
34,007,603
586.89%
4,950,930
-2.20%
5,062,376
29.71%
Cost of revenue
28,104,357
30,794,190
29,624,330
Unusual Expense (Income)
NOPBT
5,903,246
(25,843,260)
(24,561,954)
NOPBT Margin
17.36%
Operating Taxes
471,925
(3,793,758)
(209,316)
Tax Rate
7.99%
NOPAT
5,431,321
(22,049,502)
(24,352,638)
Net income
876,527
-103.61%
(24,279,526)
-0.61%
(24,429,545)
-6.98%
Dividends
Dividend yield
Proceeds from repurchase of equity
52,831
117,355,087
BB yield
-0.01%
-21.19%
Debt
Debt current
13,742,364
24,530,017
9,765,632
Long-term debt
271,731
246,575
319,335
Deferred revenue
131,595
Other long-term liabilities
3,136,074
2,499,772
2,591,085
Net debt
779,723
(72,706,004)
(109,619,627)
Cash flow
Cash from operating activities
(26,033,708)
(22,047,670)
(26,420,975)
CAPEX
(623,775)
(581,220)
(1,249,155)
Cash from investing activities
(327,657)
13,379,143
(99,563,032)
Cash from financing activities
30,347,453
11,124,649
120,262,173
FCF
(12,420,874)
(20,956,603)
(20,259,576)
Balance
Cash
102,727,823
97,480,596
103,695,691
Long term investments
(89,493,451)
2,000
16,008,904
Excess cash
11,533,992
97,235,049
119,451,476
Stockholders' equity
(119,135,388)
(128,637,400)
(93,876,483)
Invested Capital
263,843,012
250,466,996
228,275,519
ROIC
2.11%
ROCE
3.94%
EV
Common stock shares outstanding
38,243
38,244
32,010
Price
24,350.00
5.64%
23,050.00
33.24%
17,300.00
-50.53%
Market cap
931,221,482
5.64%
881,528,372
59.19%
553,765,717
-50.12%
EV
936,605,086
804,722,008
444,039,002
EBITDA
7,841,963
(23,986,437)
(22,922,024)
EV/EBITDA
119.44
Interest
1,085,459
406,636
316,400
Interest/NOPBT
18.39%